NSCLC and the alternative pathway of NF-κB: uncovering an unknown relation.

Virchows Archiv : an International Journal of Pathology
Fotinos-Ioannis D DimitrakopoulosHaralabos P Kalofonos

Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide. Although our knowledge on the pathobiology of the disease has increased in the last decades, the prognosis of lung cancer patients has hardly changed. Many signaling pathways are implicated in lung carcinogenesis, but the role of the alternative pathway of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) in lung cancer pathogenesis and progression has not been investigated. The aim of our study was to investigate the role of this pathway in non-small cell lung cancer (NSCLC) patients. NF-κB2 and RelB protein expression was retrospectively assessed by immunohistochemistry in tissue samples from 109 NSCLC patients. RelB and NF-κB2 protein levels differed between tumors and adjacent nonneoplastic lung parenchyma. Cytoplasmic immunoreactivity of NF-κB2 and RelB was correlated with tumor stage (p = 0.03 and p = 0.016, respectively). In addition, cytoplasmic NF-κB2 levels were related to tumor grade (p = 0.046). Expression of RelB in the cytoplasm was tumor histologic type-specific, with squamous cell carcinomas having the highest protein levels. Nuclear expression of RelB and NF-κB2 differed between tumor and nonneoplastic tissues, possibly in...Continue Reading

References

Apr 1, 1997·Seminars in Cancer Biology·M J May, S Ghosh
Dec 22, 1999·Oncogene·B Rayet, C Gélinas
May 4, 2004·Nature Reviews. Molecular Cell Biology·Lin-Feng Chen, Warner C Greene
Sep 24, 2004·Cancer Cell·Bharat B Aggarwal
Aug 19, 2005·American Journal of Respiratory Cell and Molecular Biology·York E Miller
Jun 27, 2006·The Annals of Thoracic Surgery·Zhenfa ZhangChangli Wang
Aug 26, 2006·Applied Immunohistochemistry & Molecular Morphology : AIMM·Clive R Taylor
Sep 8, 2006·Biochemical Pharmacology·Francesco Pacifico, Antonio Leonardi
Oct 5, 2006·Cancer Research·Matvey LukashevJeffrey L Browning
Oct 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laurent LessardFred Saad
Dec 22, 2006·Nature Reviews. Molecular Cell Biology·Neil D Perkins
Mar 14, 2007·Current Pharmaceutical Design·Takashi OkamotoKaori Asamitsu
Apr 6, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Mitsuo SatoJohn D Minna
Sep 28, 2007·Annals of Surgical Oncology·Dianliang ZhangChunbao Guo
Dec 7, 2007·Cancer Research·Fei Chen, Vince Castranova
Feb 13, 2008·Cell·Matthew S Hayden, Sankar Ghosh
Jun 25, 2008·International Reviews of Immunology·Fei ChenVince Castranova
Sep 26, 2008·The New England Journal of Medicine·Roy S HerbstScott M Lippman
Feb 10, 2009·Clinical Science·Ee Tsin Wong, Vinay Tergaonkar
May 29, 2009·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Aug 4, 2009·Seminars in Immunology·Angelica S I Loskog, Aristides G Eliopoulos
Mar 23, 2010·Cell·Sergei I GrivennikovMichael Karin

❮ Previous
Next ❯

Citations

Oct 20, 2012·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jin XiaQingxia Fan
Mar 29, 2018·Scientific Reports·Foteinos-Ioannis D DimitrakopoulosHaralabos P Kalofonos
Apr 19, 2018·Scientific Reports·Jamie A SaxonTimothy S Blackwell

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.